阅读说明：本技术 一种治疗肌萎缩侧索硬化的方法和药物 (Method and medicine for treating amyotrophic lateral sclerosis ) 是由 李季男 于 2020-05-11 设计创作，主要内容包括：本发明公开了一种治疗肌萎缩侧索硬化(ALS)的方法,包括给药受试者治疗有效量的纤溶酶原途径激活剂。本发明还公开了用于治疗肌萎缩侧索硬化的包含纤溶酶原途径激活剂的药物组合物、制品、试剂盒。(The present invention discloses a method of treating Amyotrophic Lateral Sclerosis (ALS) comprising administering to a subject a therapeutically effective amount of a plasminogen pathway activator. The invention also discloses pharmaceutical compositions, articles of manufacture, kits comprising plasminogen pathway activators for the treatment of amyotrophic lateral sclerosis.)

A method of treating Amyotrophic Lateral Sclerosis (ALS) comprising administering to a subject having Amyotrophic Lateral Sclerosis (ALS) a therapeutically effective amount of a plasminogen pathway activator.

The method of claim 1, wherein the plasminogen pathway activator has one or more activities selected from the group consisting of: prolonging life and median survival time, delaying muscle atrophy and muscle force decline, slowing down the speed of weight loss, reducing injury, degeneration and necrosis of anterior cord cells, promoting synthesis of anterior cord ChAT, promoting functional recovery of cholinergic neurons, promoting expression of anterior cord synaptophysin, expressing SMN protein of anterior cord, promoting inflammatory repair of anterior cord, and promoting repair of synaptic injury.

The method of claim 1, wherein the plasminogen pathway activator ameliorates a symptom of muscle atrophy, muscle force decline, spasm, and/or fasciculation in the subject.

The method of claim 1, wherein the plasminogen pathway activator reduces weight loss and/or prolongs survival of the subject.

The method of claim 1, wherein the plasminogen pathway activator improves muscle tone in the subject.

The method of claim 1, wherein the plasminogen pathway activator promotes recovery of muscle function in the subject.

The method of claim 1, wherein the plasminogen pathway activator promotes repair of damage to anterior spinal cord neurons in the subject.

The method of any one of claims 1 to 7, wherein the plasminogen pathway activator is administered in combination with one or more other drugs and/or methods of treatment.

The method of any one of claims 1-8, wherein the plasminogen pathway activator is administered intravenously, subcutaneously, intramuscularly, intrathecally, nasally by inhalation, by inhalation nebulization, by nasal drops, or by eye drops.

The method of any one of claims 1-9, wherein the plasminogen pathway activator is a component of the plasminogen activation pathway.

The method of claim 10, the component of the plasminogen-activating pathway is plasminogen.

The method of claim 11, wherein the plasminogen has at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to sequence 2, 6, 8, 10 or 12 and still has plasminogen activity.

The method of claim 11, the plasminogen is a plasminogen active fragment, and still has plasminogen activity and/or lysine binding activity.

The method of claim 11, said plasminogen is selected from Glu-plasminogen, Lys-plasminogen, miniplasminogen, microplasminogen, delta-plasminogen or variants thereof retaining plasminogen activity.

The method of claim 11, the plasminogen is native or synthetic human plasminogen, or a variant or fragment thereof still retaining plasminogen activity and/or lysine binding activity.